Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Nguyen Thu Huong

Nguyen Thu Huong

Gunma University Graduate School of Medicine, Japan

Title: Evaluation of diffusion weighted MR Imaging and 18F-FDG PET for monitoring triple negative breast cancer response to Cisplatin treatment

Biography

Biography: Nguyen Thu Huong

Abstract

Objective: To evaluate the potential of 18F-FDG PET and diffusion weighted MR Imaging (DWI) in predicting response of triple negative breast cancer (TNBC) to Cisplatin treatment. Methods: Cisplatin (10 mg/kg) was injected one shot intraperitoneally into TNBC tumor bearing mice. Animals were imaged on PET and MRI scanners dedicated to animal use before treatment (day 0) and days 3 and 7 after treatment. The highest standardized uptake value (SUVmax) and the average of apparent diffusion coefficient value (ADCmean) were measured. Results: We evaluated tumor growth of the non-treated mice (n=8) and treatment mice. Treated mice were divided into the response group (n=7) and the no response group (n=7) based on whether the  tumor growth was similar to or slower than that of the non-treated mouse. SUVmax value on day 3 and day 7 (SUV3, SUV7) showed significant difference between the response group and no response group (P<0.05), however, ratio of SUVmax on day 7 to day 0 (SUV7/0) showed no significant diffrence between three groups (P> 0.05). ADCmean value on day 0 (ADC0) of the response group was significantly lower than that of the no response group (P<0.01). The ratio of ADCmean on day 7 to day 0 (ADC7/0) showed significant difference between three groups (P<0.01), and ADC7/0 of the response group were significantly higher than those of control group and no response group. Conclusions: ADC0, ADC7/0 are potential early predictors of response of TNBC to Cisplatin treatment.